With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...
It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...
To qualify for advanced manufacturing technology designation from the FDA, a company must present a manufacturing approach that incorporates a new technology or uses an established technology in a ...
A roundtable discussion reveals how hybrid distributed models could provide a bridge from centralized cell-therapy ...
The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...
DUBLIN--(BUSINESS WIRE)--The "Point-of-Care Cell and Gene Therapy Manufacturing Market - A Global and Regional Analysis: Focus on Technology, Therapeutic Area, End User, and Regional Analysis - ...
Automation, decentralized manufacturing, and supportive regulations are helping to surmount technical difficulties in cell and gene therapy manufacturing.
For NK cell expansion, engineered ARH-77 cells may end the current bottleneck by increasing yield by more than 100,000-fold in one month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results